

WEST Search History

DATE: Wednesday, September 10, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=AND</i>			
L11	l5 and amidoxime	5	L11
L10	l5 and omidoxime	0	L10
L9	l5 and diabet?	0	L9
L8	L6l5 and diabet?	0	L8
L7	L6l5 and diabete?	0	L7
L6	L5 and l2	2	L6
L5	L4 or l1	1229	L5
L4	actinic adj keratosis	736	L4
L3	L2 and l1	0	L3
L2	4308399	25	L2
L1	actinic adj keratoses	558	L1

END OF SEARCH HISTORY

=> d hist

(FILE 'HOME' ENTERED AT 18:24:06 ON 10 SEP 2003)

FILE 'REGISTRY' ENTERED AT 18:24:59 ON 10 SEP 2003

L1 1559 S AMIDOXIME
L2 1 S L1 AND NICOTINIC
L3 0 S NICOTAMIDOXIME

FILE 'CAPLUS' ENTERED AT 18:29:47 ON 10 SEP 2003

L4 538 S AMIDOXIME/TI
L5 0 S L4 AND PHARMACEUTICAL (W) COMPOSIITONS/TI
L6 1 S L4 AND PHARMACEUTICAL (W) COMPOSITIONS/TI
L7 0 S KALMAN-TAKACS/AU
L8 136 S KALMAN-T?/AU
L9 0 S L8 AND PHARMACEUTICAL (W) COMPOSITIONS/TI

FILE 'REGISTRY' ENTERED AT 18:40:02 ON 10 SEP 2003

L10 STRUCTURE UPLOADED
L11 1 S L10 SAM
L12 8 S L10 FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 18:41:03 ON 10 SEP 2003

FILE 'REGISTRY' ENTERED AT 18:41:17 ON 10 SEP 2003

FILE 'CAPLUS, MEDLINE' ENTERED AT 18:44:59 ON 10 SEP 2003
L13 3 S L12

FILE 'REGISTRY' ENTERED AT 18:46:51 ON 10 SEP 2003
L14 1 S 66611-32-3/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY
L15 0 S ACTINIC (W) KERATOS?

FILE 'CAPLUS, MEDLINE' ENTERED AT 18:49:09 ON 10 SEP 2003
L16 961 S ACTINIC (W) KERATOS?
L17 1 S L16 AND (AMIDOXIME OR HYDROXIM?)

WEST**End of Result Set**

Generate Collection

L10: Entry 2 of 2

File: DWPI

May 25, 2001

DERWENT-ACC-NO: 1997-280690

DERWENT-WEEK: 200132

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Increasing expression of molecular chaperone by eukaryotic cell by treating the cell exposed to physiological stress with hydroxylamine derivatives - used to treat e.g. metabolic, oxidative or local mechanical stress, stress caused by hypoxia, ischaemia, heat shock, radiation or toxic materials

INVENTOR: BALOGH, G ; BARABAS, M ; BR, K ; DORMAN, G ; HEGEDUS, E ; HORVATH, I ; JASZLITS, L ; JEDNAKOVITS, A ; KORANYI, L ; KURTHY, M ; LITERATI-NAGY, P ; MARVANYOS, E ; MEDZIHRADSZKY, D ; MEZES, B ; SZILBEREKY, J ; TOROK, Z ; UDVARDY, E ; UROGDI, L ; VGH, L ; BIRO, K ; DUDA, E ; FARKAS, B ; GLATZ, A ; KOVACS, E ; LITERATINAGY, P ; MEDZAIHRADSZKY, D ; VIGH, L ; HEGEDUES, E ; KUERTHY, M ; LITERATI, N P ; TOEROEK, Z ; UEROEGDI, L ; LITERATI NAGY, P ; UROEGDI, L ; KORANVI, L ; NAGY, P L ; SZULBEREKY, J ; SZIBEREKY, J

PATENT-ASSIGNEE:

ASSIGNEE	CODE
BIOREX KUTATO ES FEJLESZTO RT	BIORN
BIOREX KUTATO ES FEJLESZTOE RT	BIORN

PRIORITY-DATA: 1995HU-0003141 (November 2, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
NZ 320523 A	May 25, 2001		000	A61K031/47
WO <u>9716439</u> A1	May 9, 1997	E	179	C07D333/38
AU 9673263 A	May 22, 1997		000	C07D333/38
NO 9703059 A	September 2, 1997		000	C07D333/38
EP 801649 A1	October 22, 1997	E	000	C07D333/38
HU 76659 T	October 28, 1997		000	C12N015/67
CZ 9702072 A3	March 18, 1998		000	C07D213/89
SK 9700881 A3	April 8, 1998		000	C07D333/38
ZA 9609249 A	May 27, 1998		190	C07C000/00
JP 10512590 W	December 2, 1998		211	C07C279/18
KR 98700976 A	April 30, 1998		000	C07D333/38
BR 9607565 A	July 20, 1999		000	C07D333/38
MX 9704988 A1	July 1, 1998		000	C07D333/38
AU 720195 B	May 25, 2000		000	C07D333/38

DESIGNATED-STATES: AU BG BR CA CN CZ EE IL JP KR LT LV MX NO NZ PL RO RU SI SK TR UA US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL PT RO SE SI

CITED-DOCUMENTS: 1.Jnl.Ref; DE 2651083 ; FR 2362845 ; HU 66350 ; WO 9004584 ; WO 9008131 ; WO 9530649

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	descriptor
NZ 320523A	November 1, 1996	1996NZ-0320523	
NZ 320523A	November 1, 1996	1996WO-HU00064	
NZ 320523A		WO <u>9716439</u>	Based on
WO 9716439A1	November 1, 1996	1996WO-HU00064	
AU 9673263A	November 1, 1996	1996AU-0073263	
AU 9673263A		WO <u>9716439</u>	Based on
NO 9703059A	November 1, 1996	1996WO-HU00064	
NO 9703059A	July 1, 1997	1997NO-0003059	
EP 801649A1	November 1, 1996	1996EP-0935195	
EP 801649A1	November 1, 1996	1996WO-HU00064	
EP 801649A1		WO <u>9716439</u>	Based on
HU 76659T	November 2, 1995	1995HU-0003141	
CZ 9702072A3	November 1, 1996	1996WO-HU00064	
CZ 9702072A3	November 1, 1996	1997CZ-0002072	
CZ 9702072A3		WO <u>9716439</u>	Based on
SK 9700881A3	November 1, 1996	1996WO-HU00064	
SK 9700881A3	November 1, 1996	1997SK-0000881	
ZA 9609249A	November 4, 1996	1996ZA-0009249	
JP 10512590W	November 1, 1996	1996WO-HU00064	
JP 10512590W	November 1, 1996	1997JP-0517176	
JP 10512590W		WO <u>9716439</u>	Based on
KR 98700976A	November 1, 1996	1996WO-HU00064	
KR 98700976A	July 2, 1997	1997KR-0704575	
KR 98700976A		WO <u>9716439</u>	Based on
BR 9607565A	November 1, 1996	1996BR-0007565	
BR 9607565A	November 1, 1996	1996WO-HU00064	
BR 9607565A		WO <u>9716439</u>	Based on
MX 9704988A1	July 1, 1997	1997MX-0004988	
AU 720195B	November 1, 1996	1996AU-0073263	
AU 720195B		AU 9673263	Previous Publ.
AU 720195B		WO <u>9716439</u>	Based on

INT-CL (IPC) : A61K 31/34; A61K 31/38; A61K 31/44; A61K 31/445; A61K 31/47; A61K 31/495; C07C 0/00; C07C 215/00; C07C 259/02; C07C 279/18; C07D 213/78; C07D 213/81; C07D 213/89; C07D 215/16; C07D 215/54; C07D 217/22; C07D 217/26; C07D 271/06; C07D 295/08; C07D 295/22; C07D 307/68; C07D 333/38; C07D 405/12; C07D 409/12; C07D 413/04; C12N 5/04; C12N 5/06; C12N 15/67; C12P 21/00; C12P 21/00; C12R 1/91

ABSTRACTED-PUB-NO: WO 9716439A

BASIC-ABSTRACT:

Increasing expression of a molecular chaperone by an eukaryotic cell comprises treating the eukaryotic cell that is exposed to a physiological stress with an effective amount of hydroxylamine derivative of formula (I) or (II) or its salts and/or optically active stereoisomers to increase the expression of the molecular chaperone by the cell beyond the amount induced by the physiological stress: A = optionally substituted alkyl, aralkyl optionally substituted in the aryl and/or alkyl moiety, optionally substituted aryl or optionally substituted heteroaryl; Z = bond, O or NR3; R3 = H, optionally substituted alkyl, optionally substituted aryl or aralkyl optionally substituted in the aryl and/or alkyl moiety; R = optionally substituted alkyl; in (I) X = halo, substituted OH or amino, or mono- or di-substituted amino; and in (II) X = O or

optionally substituted imino; and R' = H, optionally substituted alkyl, optionally substituted aryl, aralkyl optionally substituted in the aryl and/or alkyl moiety, or optionally substituted acyl; and (I) optionally contain intramolecular ring structures formed by coupling X and a reactive substituent.

USE - Method is used to treat physiological stress in a cell, such as metabolic, oxidative or local mechanical stress or stress caused by hypoxia, ischaemia, heat shock, radiation or toxic materials, particularly caused by diabetes mellitus (claimed). Method is used to treat cardiovascular disease e.g. caused by atherosclerosis, coronarial disease, hypertonia, or pulmonary hypertonia provoked by physiological stress, vascular, cerebral disease e.g. cerebrovascular ischaemia, stroke, traumatic head injury, senile neurodegenerative disease, especially senile dementia, AIDS dementia, alcohol dementia, Alzheimer's disease, Parkinson's disease or epilepsy provoked by physiological stress, allergic, immune or autoimmune diseases, viral or bacterial diseases, tumours, skin and/or mucosal diseases e.g. caused by dermatosis or ulcerous disease of the gastrointestinal system provoked by physiological stress, epithelial disease of renal tubulus all caused by physiological stress or a condition caused by physiological stress that can be treated by cosmetic intervention (all claimed). Method may be used to treat ischaemia, neoplastic disease, infections caused by pathogenic microorganisms, autoimmune disease and dermatosis (all claimed). Method is used to protect the myocardium, brain tissues and kidney from tissue damage and/or necrosis caused by ischaemia (claimed). (I) may also be used in cosmetic compositions (claimed).

CHOSEN-DRAWING: Dwg.1/29

TITLE-TERMS: INCREASE EXPRESS MOLECULAR EUKARYOTIC CELL TREAT CELL EXPOSE PHYSIOLOGICAL STRESS HYDROXYLAMINE DERIVATIVE TREAT METABOLISM OXIDATION LOCAL MECHANICAL STRESS STRESS CAUSE HYPOXIA ISCHAEMIC HEAT SHOCK RADIATE TOXIC MATERIAL

DERWENT-CLASS: B05

CPI-CODES: B07-D05; B10-A18; B14-F01;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
M423 M710 M903 V753

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1997-090161